Yescarta™ is positioned to join Kymriah™Â as the second chimeric antigen receptor T cell (CAR-T) therapy to achieve regulatory approval in Canada, based on exciting news released this month from Gilead Sciences Canada. [Read more…]
Americord announces five-compartment bags and best-in-industry quality guarantee
New York, NY; February 19, 2019 — Americord Registry announced today that it will begin offering five-compartment freezing bags for all new customers storing cord blood as well as the highest quality guarantee in the industry. While industry-standard freezing bags typically contain two compartments, one holding eighty percent of the cord blood and a second holding twenty percent, Americord’s new freezing bags contain five compartments with twenty percent of the cord blood in each compartment. [Read more…]
Webinar Case Study: ‘Companion Informatics’ to Automate Immunotherapy Manufacturing and Treatment
L7 Informatics is honored to host a Free Webinar exploring a Case Study related to “‘Companion Informatics’ to Automate Immunotherapy Manufacturing and Treatment.”
Webinar:Â Companion Informatics’ to Automate Immunotherapy Manufacturing & Treatment
Genomics-driven precision medicine and regenerative medicine including cell and gene therapies require a new category of “companion informatics” software that automates and synchronizes complex data and process management. This software is applicable throughout the life-cycle of these complex therapeutics as they make their way from bench to clinical trials to bedside. [Read more…]
Signature Biologics Announces Entry Into the Perinatal Allograft Tissue Market With Commercially Available Flowable Umbilical Cord and Amniotic Allograft Tissue Products
Signature Matrix and Signature Cord are the culmination of decades of research and clinical use of perinatal tissue by applied stem cell research expert and Amazon best-selling author, Neil Riordan, PA, PhD, and his experienced research and development team.
Signature Cord is a flowable umbilical cord tissue allograft that originates from the same tissue used to manufacture the purified, expanded mesenchymal stem cell product used by Stem Cell Institute in Panama to treat a variety of chronic conditions. This product is a natural source of growth factors and hyaluronic acid, and is naturally immune evasive. Most importantly, our proprietary Signature Process of manufacturing does not alter the innate regenerative properties of the umbilical cord tissue and maintains the source material integrity required for tissue repair. [Read more…]
Sana Biotechnology, Former Juno Therapeutics Execs Co-Found New Biotech
On January 4, 2019, Sana Biotechnology became the latest regenerative medicine company to enter the marketplace, founded by former Juno Therapeutics executives Hans Bishop and Steve Harr, among other all-star executives. With operations in Seattle, WA, Cambridge, MA and San Francisco, CA, the company will be focused on creating engineered cells as medicines for patients.
Based on preliminary company statements, Sana seems to be interested in reproducing the business model and the financial success that characterized Juno Therapeutics – specifically, its ability to attract top talent from across the marketplace, accumulate investor funds, and exit for a major windfall. [Read more…]
- « Previous Page
- 1
- …
- 214
- 215
- 216
- 217
- 218
- …
- 336
- Next Page »